BioMarin Pharmaceutical
BioMarin is a global biotechnology company founded in 1997, dedicated to translating genetic discoveries into new medicines that improve human health. With a focus on genetic conditions, the company has developed eight approved medicines for conditions such as achondroplasia, severe hemophilia A, and various rare inherited and lysosomal storage diseases. BioMarin's approach involves cutting-edge science rooted in genetic insights, leading to a diverse pipeline of clinical and preclinical candidates. The company operates in over 70 countries, employs around 3,000 people, and is committed to bold science, patient-centric solutions, and community support.
Industries
Nr. of Employees
Very Large (1000+)
BioMarin Pharmaceutical
San Rafael, California, United States, North America
Patents
C-type natriuretic peptide variants to treat skeletal dysplasia in children
US-12233106-B2
View DetailsManufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
US-12188058-B2
View DetailsCompositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects
US-11918633-B2
View Details
C-type natriuretic peptide variants to treat skeletal dysplasia in children
US-12233106-B2
View DetailsManufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
US-12188058-B2
View DetailsCompositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects
US-11918633-B2
View DetailsProducts
Approved therapeutics for genetically defined rare diseases
A portfolio of marketed medicines for conditions including skeletal dysplasia, severe hemophilia A and several rare inherited and lysosomal storage diseases.
Approved therapeutics for genetically defined rare diseases
A portfolio of marketed medicines for conditions including skeletal dysplasia, severe hemophilia A and several rare inherited and lysosomal storage diseases.
Services
Support for independent medical education, external research collaborations and publication data requests for the scientific community.
Programs to support patients in accessing therapies and resources, including expanded access pathways for eligible individuals.
Support for independent medical education, external research collaborations and publication data requests for the scientific community.
Programs to support patients in accessing therapies and resources, including expanded access pathways for eligible individuals.
Expertise Areas
- Genetic medicine
- Gene therapy development
- Biologics development and enzyme-replacement therapies
- Translational research and biomarker discovery
Key Technologies
- Gene therapy platforms
- Enzyme replacement therapy approaches
- Biologics process development
- Analytical chemistry methods for biologics
News & Updates
Scheduled for August 4, 2025, to discuss financial results.
BioMarin announced the acquisition of Inozyme in July 2025.
Results reinforcing safety and efficacy presented in June 2025.
Research to improve diagnosis of hypochondroplasia.
Story of career journey influenced by purpose and opportunity.
Advances in treatment for skeletal dysplasia.
Scheduled for August 4, 2025, to discuss financial results.
BioMarin announced the acquisition of Inozyme in July 2025.
Results reinforcing safety and efficacy presented in June 2025.
Research to improve diagnosis of hypochondroplasia.
Story of career journey influenced by purpose and opportunity.
Advances in treatment for skeletal dysplasia.